Global Peptide Therapeutics Market 2016-2020

Global Peptide Therapeutics Market 2016-2020

Category : Diagnostic and Biotech
Sub Category : IVD
Published On : March  2016
Pages : 81



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About Peptide Therapeutics

Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.

Technavios analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.

The market is divided into the following segments based on geography: 
• Americas
• APAC
• EMEA

Technavio's report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceuticals

Other prominent vendors 
• AbbVie
• Advanced Accelerator Applications
• Akashi Therapeutics
• Amgen
• Anthera Pharmaceuticals
• AstraZeneca
• Bachem
• Bristol-Myers Squibb
• Cardiorentis
• Corden Pharma International
• Debiopharm
• Derma Sciences
• GlaxoSmithKline
• Hanmi Pharmaceutical
• Insmed
• Ipsen
• Johnson & Johnson
• Lonza
• Mallinckrodt
• MolMed
• Merck
• Novartis
• Nymox Pharmaceutical
• Par Pharmaceuticals
• PeptiDream
• Polypeptide Group
• Radius Health
• Repligen
• Roche
• SciClone
• Shire
• The Medicines Company
• Transition Therapeutics
• X-Gen Pharmaceuticals
• Zealand Pharma
• Zydus Cadila

Market driver 
• Increase in patient population
• For a full, detailed list, view our report 

Market challenge 
• High cost of therapy
• For a full, detailed list, view our report 

Market trend 
• Shifting focus toward untapped markets
• For a full, detailed list, view our report 

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of peptides
Peptide synthesis
Optimization of peptides
Stabilization of peptides
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Market segmentation based on route of administration
Parenteral
Oral
Pulmonary
Mucosal
PART 08: Market segmentation by drug class
Somatostatins
Vasopressin
Calcitonins
Luteinizing hormone (LH)-releasing hormone (LHRH)
Glucagon and analogs
Insulins
Other
PART 09: Market segmentation by synthesis technology
Liquid-phase peptide synthesis
Solid-phase peptide synthesis
Hybrid peptide synthesis
PART 10: Geographical segmentation
Global peptide therapeutics market segmentation by geography 2015-2020
Peptide therapeutics market in Americas
Peptide therapeutics market in EMEA
Peptide therapeutics market in APAC
PART 11: Market drivers
Increase in patient population
Advances in peptide synthesis technology
Promising pipeline
Unmet medical needs
Increase in healthcare spending
PART 12: Impact of drivers
PART 13: Market challenges
High cost of therapy
Adverse side effects
Stringent regulatory compliances
Intense market competition
PART 14: Impact of drivers and challenges
PART 15: Market trends
Growing popularity
Shifting focus toward untapped markets
Contract manufacturing
Increase in public awareness
PART 16: Vendor landscape
Competitive scenario
Eli Lilly
Novo Nordisk
Sanofi
Takeda Pharmaceutical
Teva Pharmaceuticals
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: SWOT analysis: Peptide therapeutics
Exhibit 03: Steps involved in peptide synthesis
Exhibit 04: Optimization of peptide synthesis
Exhibit 05: Methods used to stabilize peptides
Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
Exhibit 10: Global peptide therapeutics market segmentation by drug class
Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
Exhibit 25: Eli Lilly: Key takeaways
Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
Exhibit 40: Sanofi: Key takeaways
Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
Exhibit 45: Takeda Pharmaceutical: Key takeaways
Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
Exhibit 47: Teva Pharmaceuticals: Key takeaways

Enquiry Before Buy
image
Can´t read the image ? refresh here.